

THOMAS E. GETZEN

WILEY
INTERNATIONAL
EDITION

RESTRICTED!
NOT FOR SALE IN
NORTH AMERICA

HEALTH ECONOMICS

Fundamentals and Flow of Funds



SECOND
EDITION



CONTENTS

Preface xviii

Acknowledgements xxi

About the Author xxii

Foreword xxiii

1 Terms of Trade: The Flow of Funds Through the Health Care System 1

- 1.1 **WHAT IS ECONOMICS?** 2
 - Terms of Trade 3
 - Value 4
- 1.2 **THE FLOW OF FUNDS** 4
 - Health Care Spending in the United States 5
 - Sources of Funds 6
 - Health Care Providers: The Uses of Funds 8
- 1.3 **QUALITY** 10
- 1.4 **PUBLIC OR PRIVATE CHOICES** 10
- 1.5 **RESEARCH** 11
- 1.6 **TIME** 12
- 1.7 **THE STRUCTURE OF THE ECONOMY: CONTRACTS** 13
- 1.8 **ECONOMIC PRINCIPLES AS CONCEPTUAL TOOLS** 14
 - Trade 14
 - Choice: Are Benefits Greater Than Costs? 14
 - Opportunity Cost 14
 - Scarcity (Budget Constraints) 14
 - Maximization/Marginalism 15
 - Money Flows in a Circle 15
 - Contracts and Organization 15
- 1.9 **HEALTH PRINCIPLES** 15
 - Health Is Priceless 16
 - And Yet, Money Still Determines Health 16
 - Health Risks Are More Public Than Private 16
 - Individual Choices: Lifestyle Is More Than Medicine 16

Measurable Differences in Quality Over Time, or Regions, Are
Greater Than Most Differences in Choices Faced by Patients 17

1.10 HEALTH AND THE ECONOMY 17

Suggestions for Further Reading 18

Summary 18

Problems 19

Endnotes 20

2 Demand 21

2.1 NEED VERSUS DEMAND 21

2.2 THE DEMAND CURVE 22

The Diamonds-Water Paradox: An Example of Marginal Analysis 23

Ceteris Paribus 25

Derived Demand 25

Individual, Firm, and Market Demand Curves 26

2.3 MARGINAL REVENUE 26

Price Sensitivity 27

Price Elasticity and Marginal Revenue 28

Price Discrimination 30

2.4 IS PRICE THE ONLY THING THAT MATTERS? 31

2.5 PROFIT-MAXIMIZING FIRMS, SUPPLY, AND MARKETS 32

2.6 EFFICIENCY 33

Suggestions for Further Reading 34

Summary 34

Problems 36

Endnotes 38

3 Cost-Benefit and Cost-Effectiveness Analysis 39

3.1 COST-BENEFIT ANALYSIS IS ABOUT MAKING CHOICES 40

An Everyday Example: Knee Injury 40

Opportunity Cost: Looking at Alternatives 43

Expected Value 44

Maximization: Finding the Optimum 44

Average, Total, and Marginal Costs 47

**3.2 AN EXAMPLE OF MARGINAL ANALYSIS: COSTS AND BENEFITS
OF A SIXTH STOOL GUAIAAC 48**

3.3 MEASURING BENEFITS 52

Health 52

Productivity 53

	Reductions in Future Medical Costs	53
3.4	MEASURING COSTS	53
	Medical Care and Administration: Charges Versus Costs	54
	Follow-up and Treatment	54
	Time and Pain of Patient and Family	54
	Provider Time and Inconvenience	55
3.5	THE VALUE OF LIFE	55
3.6	QUALITY-ADJUSTED LIFE YEARS (QALYs)	57
	Discounting Over Time	57
	QALY League Tables	58
3.7	PERSPECTIVES: PATIENT, PAYER, GOVERNMENT, PROVIDER, SOCIETY	59
	Distribution: Whose Costs and Whose Benefits?	60
	CBA Is a Limited Perspective	60
	CBA and Public Policy Decision Making	61
	<i>Suggestions for Further Reading</i>	61
	<i>Summary</i>	62
	<i>Problems</i>	63
	<i>Endnotes</i>	65

4 Insurance 67

4.1	METHODS FOR COVERING RISKS	67
	Savings	68
	Family and Friends	68
	Charity	68
	Private Market Insurance Contracts	69
	Social Insurance	70
	Strengths and Weaknesses of Different Forms of Risk Spreading	70
4.2	WHY THIRD-PARTY PAYMENT?	71
	Variability	72
4.3	RISK AVERSION	74
4.4	ADVERSE SELECTION	75
4.5	MORAL HAZARD	77
	Welfare Losses Due to Moral Hazard	78
4.6	OPEN OR CLOSED FUNDING?	80
	<i>Suggestions for Further Reading</i>	81
	<i>Summary</i>	81
	<i>Problems</i>	82
	<i>Endnotes</i>	84

5 Insurance Contracts and Managed Care 86

- 5.1 **THIRD-PARTY TRANSACTIONS 86**
 - Tax Benefits 87
 - Who Pays? How Much? 88
- 5.2 **MANAGED CARE PLANS 89**
- 5.3 **HOW ARE BENEFITS DETERMINED? 90**
- 5.4 **TYPES OF INSURANCE PLANS 90**
 - Employer-Based Group Health Insurance 90
 - Self-Paid Private Insurance 92
 - Medicare 92
 - Medicaid 92
 - Other Government Programs and Charity 92
 - The Uninsured 94
 - State Children's Health Insurance Program 95
 - Medical Savings Accounts (MSAs) and Defined Contribution "Voucher" Plans 95
- 5.5 **A RANGE OF RISK BEARING: FIXED PREMIUMS, ADMINISTERED SERVICES ONLY, AND SELF-INSURANCE 96**
 - The Underwriting Cycle 97
- 5.6 **ERISA, TAXES, AND MANDATED BENEFITS 97**
- 5.7 **HISTORY OF HEALTH INSURANCE 99**
- 5.8 **INCENTIVES—TO PATIENTS, TO PAYERS, AND TO PROVIDERS. 102**
 - Suggestions for Further Reading* 103
 - Summary* 103
 - Problems* 104
 - Endnotes* 104

6 Physicians 106

- 6.1 **PHYSICIAN PAYMENT: HOW FUNDS FLOW IN 106**
 - Co-pays, Assignment, and Balance Billing 110
 - Physician Payment in Managed Care Plans 111
 - Incentives: Why Differences in the Type of Payment Matter 111
 - A Progression: From Prices to Reimbursement Mechanisms 112
- 6.2 **PHYSICIAN INCOMES 112**
- 6.3 **PHYSICIAN COSTS: HOW FUNDS FLOW OUT 113**
 - Physician Practice Expenses 113
 - The Labor-Leisure Choice 115
 - The Doctor's Workshop and Unpaid Hospital Inputs 116
 - Malpractice 116

6.4	THE TRANSACTION BETWEEN DOCTOR AND PATIENT	117
	Asymmetric Information	117
6.5	UNCERTAINTY	118
6.6	LICENSURE: QUALITY OR PROFITS?	119
	How Does Licensure Increase Physician Profits?	119
	Supply and Demand Response in Licensed Versus Unlicensed Professions	120
	How Does Licensure Improve Quality?	121
	A Test of the Quality Hypothesis: Strong Versus Weak Licensure	122
	<i>Suggestions for Further Reading</i>	123
	<i>Summary</i>	123
	<i>Problems</i>	124
	<i>Endnotes</i>	125

7 Medical Education, Organization, and Business Practices 127

7.1	MEDICAL EDUCATION	127
	Human Capital: Medical Education as Investment	128
7.2	THE ORIGINS OF LICENSURE AND LINKAGE TO MEDICAL EDUCATION	129
	AMA Controls Over Physician Supply, 1930–1965	130
	Breaking the Contract: The Great Medical Student Expansion of 1970–1980	132
	Building Pressure: Fixed Domestic Graduation Rates 1980–2002	132
7.3	ADJUSTING PHYSICIAN SUPPLY	133
	The Flow of New Entrants and the Stock of Physicians	133
	Immigration of International Medical Graduates	134
	Growth in Non-M.D. Physicians	134
	Balancing Supply and Incomes: Tracing the Past and Projecting the Future	135
7.4	GROUP PRACTICE: HOW ORGANIZATION AND TECHNOLOGY AFFECT TRANSACTIONS	135
7.5	KICKBACKS, SELF-DEALING, AND SIDE PAYMENTS	138
7.6	PRICE DISCRIMINATION	140
7.7	PRACTICE VARIATIONS	142
7.8	INSURANCE, PRICE COMPETITION, AND THE STRUCTURE OF MEDICAL MARKETS	145
	<i>Suggestions for Further Reading</i>	147
	<i>Summary</i>	147
	<i>Problems</i>	149
	<i>Endnotes</i>	152

8 Hospitals 154

- 8.1 FROM CHARITABLE INSTITUTIONS TO CORPORATE CHAINS:
DEVELOPMENT OF THE MODERN HOSPITAL 154
- 8.2 REVENUES: THE FLOW OF FUNDS INTO THE HOSPITAL 156
Sources of Revenues 157
- 8.3 COSTS: THE FLOW OF FUNDS OUT OF THE HOSPITAL 162
- 8.4 FINANCIAL MANAGEMENT AND COST SHIFTING 162
- 8.5 CAPITAL FINANCING 166
- 8.6 ORGANIZATION: WHO CONTROLS THE HOSPITAL AND FOR
WHAT ENDS? 169

Suggestions for Further Reading 171

Summary 171

Problems 172

Endnotes 173

9 Management and Regulation of Hospital Costs 175

- 9.1 WHY DO SOME HOSPITALS COST MORE THAN OTHERS? 175
- 9.2 HOW MANAGEMENT CONTROLS COSTS 176
Short-Run Versus Long-Run Cost Functions 176
Uncertainty and Budgeting 178
- 9.3 CONFLICT BETWEEN ECONOMIC THEORY AND ACCOUNTING
MEASURES OF PER UNIT COST 180
Timing 180
Whose Costs? 182
- 9.4 ECONOMIES OF SCALE 183
The Hospital is a Multiproduct Firm 184
Contracting Out 184
- 9.5 QUALITY AND COST 185
Technology: Cutting Costs or Enhancing Quality? 185
Improved Efficiency May Raise Total Spending 185
- 9.6 HOW DO HOSPITALS COMPETE? 186
Competing for Patients 186
Competing for Physicians 187
Competing for Contracts 187
Measuring Competitive Success 188
Measuring the Competitiveness of Markets 189
- 9.7 CONTROLLING HOSPITAL COSTS THROUGH REGULATION 189

Suggestions for Further Reading 193

Summary 193

Problems 194

Endnotes 196

10 Managed Care 197

- 10.1 **WHY MANAGED CARE? 197**
 - Costs and Quality 198
 - Management: The Distinctive Feature of Managed Care 198
 - Contractual Reforms to Reduce Costs 199
 - Reforming the Organization to Reduce Cost 200
- 10.2 **SOURCES AND USES OF FUNDS 201**
- 10.3 **THE RANGE OF MANAGED CARE PLANS 202**
 - Provider Networks 202
 - Gatekeeping 203
 - Capitation 203
 - Withholds 205
 - Utilization Review 205
- 10.4 **HOW CARE IS MANAGED: A MENTAL HEALTH EXAMPLE 206**
- 10.5 **INDIVIDUAL AND SYSTEM RISKS IN HEALTH CARE 208**
- 10.6 **KAISER: THE EVOLUTION OF AN HMO 210**
- 10.7 **OWNERSHIP AND CAPITAL MARKETS: SIGNS OF FAILURE 212**
 - GHA: A Consumer Co-op Gets Bought Out by a Franchise Chain 212
 - Corporate Advantage 213
 - U.S. Healthcare: A Profitable Growth Company 214
- 10.8 **THE ENTHOVEN "MANAGED COMPETITION" PLAN 216**
- 10.9 **IS MANAGED CARE THE SOLUTION TO RISING COSTS? 217**
 - Evidence on Cost Reductions 217
 - Risk Selection 217
 - Quality of Care 218
 - Costs Reductions in IPA HMOs, PPOs, and POS Plans 218
 - Administrative Costs and Profits 218
 - One-Time Savings? 219
- 10.10 **BACKLASH: ARE THERE LOSERS AS WELL AS WINNERS? 219**
 - Suggestions for Further Reading* 220
 - Summary* 220
 - Problems* 222
 - Endnotes* 223

11 Long-Term Care 227

- 11.1 **DEVELOPMENT OF THE LONG-TERM CARE MARKET 228**
- 11.2 **DEFINING LTC: TYPES OF CARE 230**
- 11.3 **MEDICAID: NURSING HOMES AS A TWO-PART MARKET 231**
- 11.4 **CERTIFICATE OF NEED: WHOSE NEEDS? 234**

	Money and Quality	234
	Competing for Certificates of Need, Not for Patients	235
	Evidence on the Effects of CON	236
11.5	CASE-MIX REIMBURSEMENT	236
11.6	SUBSTITUTION	238
11.7	FINANCIAL REIMBURSEMENT CYCLES	239
11.8	CONTINUING CARE RETIREMENT COMMUNITIES AND THE WEALTHY ELDERLY	241
	Medicare Catastrophic Coverage Act of 1988 and the Taxpayer Revolt	242
11.9	THE EFFECTS OF AGING ON COST AND UTILIZATION	243
	Defining Boundaries: Is Long-Term Care “Medical”?	243
	LTC Insurance	244
	The Effects of Aging	245
	<i>Suggestions for Further Reading</i>	246
	<i>Summary</i>	247
	<i>Problems</i>	248
	<i>Endnotes</i>	249

12 Pharmaceuticals 251

12.1	HOW FUNDS FLOW IN	252
	Medicare and Medicaid	253
	Inpatient Pharmaceuticals	254
12.2	USES OF FUNDS	254
	Retail Pharmacies	255
	Wholesalers	256
	Insurance Companies and PBMs	256
	Pharmaceutical Firms	256
	Cost Structure	258
12.3	HISTORY AND REGULATION OF PHARMACEUTICALS	258
12.4	RESEARCH AND DEVELOPMENT	262
12.5	PHARMACOECONOMICS AND OUTCOMES RESEARCH	265
12.6	INDUSTRY STRUCTURE AND COMPETITION	265
	Market Segmentation: Types of Buyers	266
	Contractual Responses to Pharmacy Benefits Management	267
	Value and Cost	267
	The Role of Middlemen: Distribution Versus Marketing	269
	Research Productivity	270
12.7	TRENDS: FORM FOLLOWS FUNCTION (AND MONEY)	271
	<i>Suggestions for Further Reading</i>	272
	<i>Summary</i>	273

Problems 273

Endnotes 275

13 Introduction to the Macroeconomics of Health 277

- 13.1 WHAT IS MACRO HEALTH ECONOMICS? 277
- 13.2 PROPERTIES OF THE INDIVIDUAL VERSUS PROPERTIES OF THE SYSTEM 278
- 13.3 DYNAMICS: CHANGE OVER TIME 279
- 13.4 ABSTRACTIONS AND COMPLICATIONS 280
- 13.5 THE ROLE OF GOVERNMENT (OVERVIEW OF CHAPTERS 14–18) 282

Suggestions for Further Reading 282

Problems 282

Endnotes 283

14 The Role of Government 284

- 14.1 THE FLOW OF GOVERNMENT HEALTH FUNDS 284
- 14.2 THE ROLES OF GOVERNMENT 285
 - Government is Necessary, Even for Private Exchange 285
 - Efficiency of Markets Under Conditions of Perfect Competition 287
 - Government in a Mixed Economy 287
- 14.3 LAW AND ORDER 288
- 14.4 PUBLIC GOODS AND EXTERNALITIES 289
 - Externalities 289
 - The Coase Theorem: Transaction Costs and Property Rights 290
 - Politicians: Entrepreneurs Who Try to Get Votes 291
- 14.5 MARKET FAILURE 291
 - Monopoly 291
 - Paternalism 293
- 14.6 INCOME REDISTRIBUTION AND CARE OF THE POOR 294
 - Medicaid and Medicare: Dependency or Rights? 294
- 14.7 HOW GOVERNMENT WORKS 295
 - The Voluntary Sector 296
 - Government as the Citizen's Agent 296
 - Winners and Losers 298
- 14.8 PROS AND CONS OF REGULATION AND COMPETITION 299

Suggestions for Further Reading 301

Summary 301

Problems 302

Endnotes 303

15 Public Goods and Public Health 305

- 15.1 **CHARACTERISTICS OF PUBLIC GOODS 305**
 - Privatizing Public Goods 306
 - Social Costs Depend on the Number of People 307
 - Insurance Makes Any Good More Public 307
- 15.2 **INFORMATION 308**
 - Rational Consumer Ignorance 309
 - Milk or Bread: Which is More Public? 309
- 15.3 **THE THEORY OF PURE PUBLIC GOODS 310**
 - Public Goods Make Most People Better Off, But Few Happy 312
- 15.4 **INFECTIOUS DISEASE EXTERNALITIES 313**
 - Epidemics 314
 - HIV/AIDS 315
 - The Sanitary Revolution: A Moral Campaign for Public Health 316
 - Formation of the U.S. Public Health Service 316
- 15.5 **SEX, DRUGS, AND WAR: PUBLIC HEALTH IN ACTION 317**
 - Who Counts as a Citizen? Abortion and Other Dilemmas 318
 - Addiction 319
 - War and Public Health 319
- Suggestions for Further Reading* 321
- Summary* 321
- Problems* 321
- Endnotes* 322

16 Economic History, Population Growth, and Medical Care 324

- 16.1 **ECONOMIC GROWTH HAS DETERMINED THE SHAPE OF HEALTH CARE 324**
- 16.2 **BIRTH RATES, DEATH RATES, AND POPULATION GROWTH 325**
- 16.3 **THE STONE AGE 325**
- 16.4 **THE AGRICULTURAL AGE 326**
 - Investment and Trade 327
 - Civilization, War, and Government 327
 - The Decline of Civilizations Leads to Population Declines 328
 - The Plague 329
 - Food Supply Determines Population 329
 - The Rise of Economics 329
 - The Malthusian Hypothesis 330
- 16.5 **THE INDUSTRIAL AGE 331**
 - Why Malthus Was Wrong 331
 - Demographic Transition 332

	Demographic Change, Income Distribution, and the Rise of the Middle Classes	334
16.6	THE INFORMATION AGE	335
16.7	INCOME AND HEALTH	336
	Income and the Value,of Medical Care	338
16.8	REDUCING UNCERTAINTY: THE VALUE OF LIFE AND ECONOMIC SECURITY	339
	The Value of Risk Reduction	339
	Social Security and Health Insurance	339
	Preconditions for Changing Medical Organization	340
16.9	THE RISE OF MEDICAL TECHNOLOGY	341
	<i>Suggestions for Further Reading</i>	343
	<i>Summary</i>	343
	<i>Problems</i>	345
	<i>Endnotes</i>	346

17 International Comparisons of Health and Health Expenditures 349

17.1	WIDE DIFFERENCES AMONG NATIONS	349
	Size of the Market	351
17.2	MICRO VERSUS MACRO ALLOCATION: HEALTH AS A NATIONAL LUXURY GOOD	352
17.3	CAUSALITY: DOES MORE SPENDING IMPROVE HEALTH?	354
17.4	LOW-INCOME COUNTRIES	356
	Sudan	357
	Health Care in Kenya	358
17.5	MIDDLE-INCOME COUNTRIES	359
	The Health Care System of Mexico	360
	Poland	361
17.6	HIGH-INCOME COUNTRIES	363
	Costs and Cost Control	363
	Japan	365
	The German Health System	368
17.7	INTERNATIONAL TRADE IN HEALTH CARE	370
	Pharmaceuticals	371
	Equipment	371
	Services	371
	People and Ideas	372
	<i>Suggestions for Further Reading</i>	372
	<i>Summary</i>	373
	<i>Problems</i>	374
	<i>Endnotes</i>	374

18 Dynamics of National Health Spending 376

- 18.1 MICRO AND MACRO PERSPECTIVES ON SPENDING 376
- 18.2 THE CONSUMPTION FUNCTION 377
The Permanent Income Hypothesis 378
Income Elasticity and Shared Income 379
- 18.3 DYNAMICS 380
Permanent Income and Adjustment of Health Spending to GDP 382
Adjustment to Inflation 383
A Dynamic Model of U.S. Health Expenditures 385
- 18.4 GOVERNMENT COST CONTROLS: SPENDING GAPS AND THE PUSH TO REGULATE 386
Price Controls: The “ESP” Program 388
The Voluntary Effort 389
Prospective Payment System with Diagnosis-Related Groups 390
Why Do People Believe Cost Controls Work? 391
- 18.5 “SPENDING” IS MOSTLY LABOR 391
Employment 392
Wages 394
Suggestions for Further Reading 396
Summary 396
Problems 397
Endnotes 399

19 Value for Money in the Future of Health Care 401

- 19.1 FORCING THE QUESTION: WHO GETS HEALTHY AND WHO GETS PAID? 401
- 19.2 SPENDING MONEY OR PRODUCING HEALTH? 402
- 19.3 ALLOCATION, ALLOCATION, ALLOCATION 404
- 19.4 DYNAMIC EFFICIENCY 405
- 19.5 THE FUTURE 406
Suggestions for Further Reading 407
Summary 408
Problems 408
Endnotes 409

Glossary 411**Index** 421